DMAC (DiaMedica Therapeutics) Additional Paid-In Capital: $231.32 Mil(As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DMAC DiaMedica Therapeutics Inc DMAC
31 GF Score
Price $6.75
! 2 Warning Signs
View Full Analysis

What is DiaMedica Therapeutics Additional Paid-In Capital?

DiaMedica Therapeutics DMAC +2.97% 31 Additional Paid-In Capital is $231.32 Mil as of Jun. 2026. GuruFocus rates DMAC with a GF Score™ of 31/100. The stock has 2 warning signs investors should review.


DiaMedica Therapeutics's quarterly additional paid-in capital increased from Dec. 2025 ($228.83 Mil) to Mar. 2026 ($230.07 Mil) and increased from Mar. 2026 ($230.07 Mil) to Jun. 2026 ($231.32 Mil).

DiaMedica Therapeutics's annual additional paid-in capital increased from Dec. 2023 ($166.61 Mil) to Dec. 2024 ($180.70 Mil) and increased from Dec. 2024 ($180.70 Mil) to Dec. 2025 ($228.83 Mil).

DiaMedica Therapeutics Additional Paid-In Capital Related Terms

DiaMedica Therapeutics Additional Paid-In Capital Historical Data

* Premium members only.

The historical data trend for DiaMedica Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DiaMedica Therapeutics Additional Paid-In Capital Chart

DiaMedica Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 126.58 128.08 166.61 180.70 228.83

DiaMedica Therapeutics Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 182.59 215.60 228.83 230.07 231.32
DMAC
31GF Score
DiaMedica Therapeutics Inc DMAC
Additional Paid-In Capital is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

DiaMedica Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)
What does a Additional Paid-In Capital of $231.32 Mil mean?
DiaMedica Therapeutics (DMAC) has a Additional Paid-In Capital of $231.32 Mil as of Jun. 2026. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on DiaMedica Therapeutics and its competitors.
Is DiaMedica Therapeutics' Additional Paid-In Capital too high?
DiaMedica Therapeutics' current Additional Paid-In Capital is $231.32 Mil. Overall, DiaMedica Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does DiaMedica Therapeutics' Additional Paid-In Capital compare to SABS and AGEN?
DiaMedica Therapeutics' Additional Paid-In Capital of $231.32 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Additional Paid-In Capital for a Biotechnology company?
A good Additional Paid-In Capital depends on the Biotechnology industry context. However, Additional Paid-In Capital should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Additional Paid-In Capital mean?
A high Additional Paid-In Capital can signal that a stock is expensive relative to its fundamentals. Additional paid-in capital is the capital a company raises in excess of par value. View historical data on DiaMedica Therapeutics and its competitors. DiaMedica Therapeutics's current Additional Paid-In Capital is $231.32 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is DiaMedica Therapeutics stock overvalued right now?
DiaMedica Therapeutics (DMAC) has a current Additional Paid-In Capital of $231.32 Mil. The current Additional Paid-In Capital is $231.32 Mil. DiaMedica Therapeutics' overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Additional Paid-In Capital calculated?
Additional Paid-In Capital is calculated from a company's financial statements. For DiaMedica Therapeutics (DMAC), the current Additional Paid-In Capital is $231.32 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

DiaMedica Therapeutics Business Description

Address 301 Carlson Parkway, Suite 210, Minneapolis, MN, USA, 55305
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.
31GF Score

Get the complete analysis for DMAC

Additional Paid-In Capital is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$6.75
Price